The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has signed a Declaration of Collaboration (DoC) with AbbVie, an American publicly traded biopharmaceutical company, during GITEX Global 2022.
The joint agreement, signed by Dr. Jamal Mohammed Al Kaabi, Under-Secretary of DoH, and Mr. Hassan Sabbah, General Manager of Abbvie Gulf, puts forward a collaboration plan between the two entities focused on three key pillars, research and clinical trials, innovation and health technology assessment, AbbVie manufacturing in Abu Dhabi and medical education.
Through this agreement, DoH aims to reinforce Abu Dhabi’s position as a life sciences hub by enhancing innovation, healthcare services and treatments available to patients in the Emirate.
The three pillars of collaboration include increasing the number and quality of clinical trials in Abu Dhabi, exploring opportunities to conduct early-phase clinical trials, showcasing innovative healthcare solutions, testing and further developing solutions by healthcare innovators, exploring the potential of local manufacturing and secondary packaging of AbbVie products, supporting Abu Dhabi in building its life sciences capabilities by exploring opportunities to develop, test, adopt and manufacture new drugs, therapeutics and technologies and educational collaborations to establish centers of excellence across different therapy areas.
Dr. Jamal Mohammed Al Kaabi Undersecretary – Abu Dhabi DoH
“Under the directives of the UAE’s wise leadership, Abu Dhabi has successfully consolidated its position as the destination of choice to some of the world’s most distinguished biopharmaceutical and healthcare companies as they advance their business in healthcare and expand operations. Today, the Emirate leads a pioneering healthcare model equipped with advanced infrastructure in line with best international standards and practices, in addition to innovative logistical capabilities and smart information exchange tools that make Abu Dhabi an ideal destination for global healthcare players.”
Mr. Sabbah commented that “I am pleased to announce the Declaration of Collaboration signing with the Abu Dhabi DoH, an important partner and stakeholder. At AbbVie, we are committed to building a stronger partnership with all stakeholders and finding opportunities to work closely on important initiatives such as Clinical Research, Innovation and Health Technology Assessment, Medical Education, and other areas of mutual interest. We believe with this partnership, we will advance medical care to provide better access to medication for our patients. We look forward to seeing the benefits of this partnership in the near future.”
